Zebrauskaite Aiste, Ziubryte Greta, Mackus Lukas, Lieponyte Austeja, Kairyte Evelina, Unikas Ramunas, Jarusevicius Gediminas
Clinic of Cardiology, Hospital of Lithuanian University of Health Sciences Kaunas Clinics, 50161 Kaunas, Lithuania.
Faculty of Medicine, Lithuanian University of Health Sciences, 50161 Kaunas, Lithuania.
J Cardiovasc Dev Dis. 2023 Sep 19;10(9):402. doi: 10.3390/jcdd10090402.
Contrast-induced acute kidney injury is the leading cause of iatrogenic acute nephropathy. Development of contrast-induced nephropathy (CIN) increases the risk of adverse long- and short-term patients outcomes, the hospital costs, and length of hospitalization. There are a couple of methods described for CIN prevention (statin prescription, prehydration, contrast media (CM) clearance from the blood system, and decrease amounts of contrast volume). The CM volume to patient's creatinine clearance ratio is the main factor to predict the risk of CIN development. The safe CM to creatinine clearance ratio limits have been established. The usage of CM amount depends on personal operators habits and inside center regulations. There is no standardized contrast usage protocol worldwide. The aim of this study was to establish an easy to use, cheap, and efficient protocol to estimate a personalized safe CM dose limit for every patient based on their kidney function. These limits are announced during the "Time Out" before the procedure. Our study included 519 patients undergoing interventional coronary procedures: 207 patients into the "Optimal Contrast Volume" arm and 312 into the control group. Applying the protocol into a daily clinical practice leads to a significant reduction in CM volume used for all type of procedures and the development of CIN in comparison with a control group.
对比剂诱导的急性肾损伤是医源性急性肾病的主要原因。对比剂肾病(CIN)的发生会增加患者短期和长期不良结局、医院费用以及住院时间的风险。目前已描述了几种预防CIN的方法(他汀类药物处方、预水化、从血液系统清除对比剂以及减少对比剂用量)。对比剂体积与患者肌酐清除率的比值是预测CIN发生风险的主要因素。已确定了安全的对比剂与肌酐清除率比值限值。对比剂用量的使用取决于个人操作者的习惯和中心内部规定。全球尚无标准化的对比剂使用方案。本研究的目的是建立一种易于使用、廉价且有效的方案,根据患者的肾功能为每位患者估算个性化的安全对比剂剂量限值。这些限值在手术前的“暂停”期间公布。我们的研究纳入了519例接受介入性冠状动脉手术的患者:207例患者进入“最佳对比剂体积”组,312例进入对照组。与对照组相比,将该方案应用于日常临床实践可显著减少所有类型手术中使用的对比剂体积以及CIN的发生。